SCHEMBL3012673

SCHEMBL3012673

Cc1ccccc1-c1csc(N2CCN(S(=O)(=O)c3cccc(C(F)(F)F)c3)CC2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.56
HTT P42858 2/20 0.55
RAF1 P04049 1/20 0.51
BRAF P15056 1/20 0.51
GBA1 P04062 2/20 0.50
KDM4E B2RXH2 2/20 0.49
HSD11B1 P28845 1/20 0.49
MAPT P10636 4/20 0.48
USP2 O75604 1/20 0.48
RECQL P46063 1/20 0.48
HSD17B10 Q99714 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
ALDH1A1 P00352 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
AR P10275 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
PKM P14618 1/20 0.45
PKLR P30613 1/20 0.45
MEN1 O00255 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006430 0.94 POLB (0.57) POLBHTTRAF1BRAFGBA1
SCHEMBL3015616 0.91 POLB (0.54) POLBHTTRAF1BRAFGBA1
SCHEMBL3007870 0.90 POLB (0.58) POLBHTTRAF1BRAFGBA1
SCHEMBL3015486 0.88 HSD17B10 (0.54) POLBHTTRAF1BRAFGBA1
SCHEMBL3019761 0.87 ALDH1A1 (0.55) POLBHTTGBA1MAPTUSP2
SCHEMBL3012403 0.87 POLB (0.56) POLBHTTRAF1BRAFGBA1
SCHEMBL3018379 0.86 HTT (0.62) POLBHTTGBA1KDM4EHSD11B1
SCHEMBL3010748 0.86 POLB (0.55) POLBHTTRAF1BRAFGBA1
SCHEMBL3017554 0.86 POLB (0.54) POLBHTTGBA1KDM4EHSD11B1
SCHEMBL3010804 0.86 ALDH1A1 (0.59) POLBHTTGBA1KDM4EHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA POLB 4649/4885HTT 2/4885RAF1 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.